Association Between Malignancy and Topical Use of Pimecrolimus | Allergy and Clinical Immunology | JAMA Dermatology | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.239.150.57. Please contact the publisher to request reinstatement.
1.
Eichenfield  LF, Tom  WL, Chamlin  SL,  et al.  Guidelines of care for the management of atopic dermatitis, section 1: diagnosis and assessment of atopic dermatitis.  J Am Acad Dermatol. 2014;70(2):338-351.PubMedGoogle ScholarCrossref
2.
Hay  RJ, Johns  NE, Williams  HC,  et al.  The global burden of skin disease in 2010: an analysis of the prevalence and impact of skin conditions.  J Invest Dermatol. 2014;134(6):1527-1534.PubMedGoogle ScholarCrossref
3.
Siegfried  EC, Jaworski  JC, Hebert  AA.  Topical calcineurin inhibitors and lymphoma risk: evidence update with implications for daily practice.  Am J Clin Dermatol. 2013;14(3):163-178.PubMedGoogle ScholarCrossref
4.
Euvrard  S, Kanitakis  J, Claudy  A.  Skin cancers after organ transplantation.  N Engl J Med. 2003;348(17):1681-1691.PubMedGoogle ScholarCrossref
5.
Clarke  CA, Morton  LM, Lynch  C,  et al.  Risk of lymphoma subtypes after solid organ transplantation in the United States.  Br J Cancer. 2013;109(1):280-288.PubMedGoogle ScholarCrossref
6.
Zwald  FO, Brown  M.  Skin cancer in solid organ transplant recipients: advances in therapy and management, part I: epidemiology of skin cancer in solid organ transplant recipients.  J Am Acad Dermatol. 2011;65(2):253-261.PubMedGoogle ScholarCrossref
7.
Tessari  G, Girolomoni  G.  Nonmelanoma skin cancer in solid organ transplant recipients: update on epidemiology, risk factors, and management.  Dermatol Surg. 2012;38(10):1622-1630.PubMedGoogle ScholarCrossref
8.
Margolis  DJ, Apter  AJ, Gupta  J,  et al.  The persistence of atopic dermatitis and filaggrin (FLG) mutations in a US longitudinal cohort.  J Allergy Clin Immunol. 2012;130(4):912-917.PubMedGoogle ScholarCrossref
9.
Kapoor  R, Menon  C, Hoffstad  O, Bilker  W, Leclerc  P, Margolis  DJ.  The prevalence of atopic triad in children with physician-confirmed atopic dermatitis.  J Am Acad Dermatol. 2008;58(1):68-73.PubMedGoogle ScholarCrossref
10.
Kapoor  R, Hoffstad  O, Bilker  W, Margolis  DJ.  The frequency and intensity of topical pimecrolimus treatment in children with physician-confirmed mild to moderate atopic dermatitis.  Pediatr Dermatol. 2009;26(6):682-687.PubMedGoogle ScholarCrossref
11.
Margolis  JS, Abuabara  K, Bilker  W, Hoffstad  O, Margolis  DJ.  Persistence of mild to moderate atopic dermatitis.  JAMA Dermatol. 2014;150(6):593-600.PubMedGoogle ScholarCrossref
12.
Williams  HC, Burney  PG, Hay  RJ,  et al.  The U.K. Working Party’s Diagnostic Criteria for Atopic Dermatitis, I: derivation of a minimum set of discriminators for atopic dermatitis.  Br J Dermatol. 1994;131(3):383-396.PubMedGoogle ScholarCrossref
13.
Fleiss  JL, Levin  B, Palk  MC.  Statistical Methods for Rates and Proportions. 3rd ed. Hoboken, NJ: John Wiley & Sons; 2003.
14.
Berg  D, Otley  CC.  Skin cancer in organ transplant recipients: epidemiology, pathogenesis, and management.  J Am Acad Dermatol. 2002;47(1):1-17.PubMedGoogle ScholarCrossref
15.
Schneeweiss  S, Doherty  M, Zhu  S,  et al.  Topical treatments with pimecrolimus, tacrolimus and medium- to high-potency corticosteroids, and risk of lymphoma.  Dermatology. 2009;219(1):7-21.PubMedGoogle ScholarCrossref
16.
Arellano  FM, Wentworth  CE, Arana  A, Fernández  C, Paul  CF.  Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis.  J Invest Dermatol. 2007;127(4):808-816.PubMedGoogle ScholarCrossref
17.
Fonacier  L, Spergel  J, Charlesworth  EN,  et al; American College of Allergy, Asthma and Immunology; American Academy of Allergy, Asthma and Immunology.  Report of the Topical Calcineurin Inhibitor Task Force of the American College of Allergy, Asthma and Immunology and the American Academy of Allergy, Asthma and Immunology.  J Allergy Clin Immunol. 2005;115(6):1249-1253.PubMedGoogle ScholarCrossref
18.
Boyle  TJ, Coles  RE, Kizilbash  AM, Lyerly  HK.  Effects of cyclosporine on human B-cell lymphoma development in vivo.  Surg Oncol. 1992;1(1):79-86.PubMedGoogle ScholarCrossref
19.
Van Leent  EJ, Ebelin  ME, Burtin  P, Dorobek  B, Spuls  PI, Bos  JD.  Low systemic exposure after repeated topical application of pimecrolimus (Elidel), SD Z ASM 981, in patients with atopic dermatitis.  Dermatology. 2002;204(1):63-68.PubMedGoogle ScholarCrossref
20.
Stiehm  ER, Roberts  RL, Kaplan  MS, Corren  J, Jaracz  E, Rico  MJ.  Pneumococcal seroconversion after vaccination for children with atopic dermatitis treated with tacrolimus ointment.  J Am Acad Dermatol. 2005;53(2)(suppl 2):S206-S213.PubMedGoogle ScholarCrossref
21.
Papp  KA, Breuer  K, Meurer  M,  et al.  Long-term treatment of atopic dermatitis with pimecrolimus cream 1% in infants does not interfere with the development of protective antibodies after vaccination.  J Am Acad Dermatol. 2005;52(2):247-253.PubMedGoogle ScholarCrossref
Original Investigation
June 2015

Association Between Malignancy and Topical Use of Pimecrolimus

Author Affiliations
  • 1Department of Biostatistics and Epidemiology, University of Pennsylvania Perelman School of Medicine, Philadelphia
  • 2Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia
  • 3Valeant Pharmaceuticals International, Bridgewater, New Jersey
JAMA Dermatol. 2015;151(6):594-599. doi:10.1001/jamadermatol.2014.4305
Abstract

Importance  A black box warning describes a potential risk of malignancy associated with topical use of pimecrolimus to treat atopic dermatitis due to its similarity to oral calcineurin inhibitors used in solid-organ transplantation and spontaneous reporting of malignancies, including lymphomas and cutaneous malignancies.

Objective  To evaluate the risk of malignancy in a postmarketing study of children exposed to pimecrolimus.

Design, Setting, and Participants  A longitudinal cohort study among a nationwide ongoing long-term cohort of children enrolled in the Pediatric Eczema Elective Registry (PEER) who had a history of atopic dermatitis and pimecrolimus use with data available up through May 2014.

Main Outcomes and Measures  Reports of malignancy among those in the PEER compared with expected rates from the Surveillance, Epidemiology, and End Results (SEER) program.

Results  Overall, 7457 children were enrolled in the PEER, for a total of 26 792 person-years. Children used a mean (SD) of 793 (1356) g of pimecrolimus when enrolled in the study. As of May 2014, five malignancies had been reported. These include 2 leukemias, 1 osteosarcoma, and 2 lymphomas. No skin cancers were reported. The standardized incidence ratio for all malignancies (primary outcome) based on the age-standardized SEER population was 1.2 (95% CI, 0.5-2.8). As secondary analyses, the standardized incidence ratios (based on 2 cases for each) were 2.9 (95% CI, 0.7-11.7) for lymphoma and 2.0 (95% CI, 0.5-8.2) for leukemia. None of these findings were statistically significant.

Conclusions and Relevance  Based on more than 25 000 person-years of follow-up, it seems unlikely that topical pimecrolimus as it was used in the PEER cohort to treat atopic dermatitis is associated with an increased risk of malignancy.

×